Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Abstract | Full HTML Article | PDF ecancer 13 937 / https://doi.org/10.3332/ecancer.2019.937


Depression and quality of life in patients with breast cancer undergoing chemotherapy and monoclonal antibodies

Background: Depression is one of the major psychiatric morbidities in cancer patients. The purpose of our study was to evaluate the impact of depressive symptoms in the quality of life (QoL) of patients with breast cancer undergoing chemotherapy and monoclonal antibodies treatments.

Methods: Observational, cross-sectional study conducted between April and November 2016. To evaluate the QoL, the EORTC QLQ-C30 and QLQ-BR23 questionnaire were used. The patients were screened for depressive symptoms using the Hospital Anxiety and Depression Scale (HADS-D) and those with a positive HADS-D positive questionnaire were referenced to the Psychiatry and Mental Health Department for further assessment and follow-up.

Results: We included 45 female patients. Sixteen (35.6%) patients had a positive HADS-D questionnaire and depressive symptoms confirmed by a psychiatric physician. Of those patients, 7 (15.6%) had a major depressive episode confirmed by psychiatric interview. There was a significant association of depressive symptoms with the future perspectives scale (p = 0.022), breast symptoms scale (p = 0.011) and arm symptom scale (p = 0.005). Significant differences were found in the fatigue (p = 0.024), pain (p = 0.037) and dyspnea (p = 0.009) subscales being worse in patients with depressive symptoms. The association between having depressive symptoms or not was shown to be significant or marginally significant for the variables stage of the tumour (p = 0.057), presence of distant metastasis (p = 0.072) and previous diagnosis of depression (p = 0.011). The patients treated with regimens containing monoclonal antibodies presented better outcomes in various subscales of the EORTC QLQ-C30 and QLQ-B23 questionnaires than those patients treated with chemotherapy regimens without monoclonal antibodies.

Conclusions: Despite the small sample of our study, this study provided evidence that depressive symptoms in patients with breast cancer undergoing chemotherapy and monoclonal antibodies treatments detrimentally reduced various aspects of QoL.

Keywords: breast neoplasm, quality of life, depression, chemotherapy, antibodies, monoclonal

Loading Article Metrics ... Please wait

Related articles

Conference Report: Cancer in pregnancy: an association to make one shiver—highlights from ‘Cancer in pregnancy: 15 years after’, 10–11 October 2019, Milan, Italy

Abstract | Full Article | PDF Published: 03 Dec 2019 / https://doi.org/10.3332/ecancer.2019.981

Review: Advances in pain management for older patients with cancer

Abstract | Full Article | PDF Published: 03 Dec 2019 / https://doi.org/10.3332/ecancer.2019.980

Case Report: Can we trust tumour markers in pregnancy after breast cancer? A case of elevated CA 15-3 in the third trimester of pregnancy normalising after delivery

Abstract | Full Article | PDF Published: 26 Nov 2019 / https://doi.org/10.3332/ecancer.2019.979

Research: Awareness of human papilloma virus and cervical cancer prevention among Cypriot female healthcare workers

Abstract | Full Article | PDF Published: 20 Nov 2019 / https://doi.org/10.3332/ecancer.2019.978

Case Report: Case report of a 65-year-old man with biatrial metastatic localisation from poorly differentiated cutaneous squamous cell carcinoma

Abstract | Full Article | PDF Published: 19 Nov 2019 / https://doi.org/10.3332/ecancer.2019.977

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation